Scyllo-Inositol (Standard)

Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease[1][2][3].

Product Specifications

CAS Number

[488-59-5]

UNSPSC

12352211

Target

Amyloid-β; α-synuclein

Related Pathways

Neuronal Signaling

Field of Research

Neurological Disease

Smiles

O[C@H]1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1O)O)O)O)O

Molecular Formula

C6H12O6

Molecular Weight

180.16

References & Citations

[1]Ibrahim T, et al. α-Synuclein aggregation, seeding and inhibition by scyllo-inositol. Biochem Biophys Res Commun. 2016 Jan 15;469 (3) :529-34.|[2]Lai AY, et al. scyllo-Inositol promotes robust mutant Huntingtin protein degradation. J Biol Chem. 2014 Feb 7;289 (6) :3666-76.|[3]Choi JK, et al. Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer's disease mouse models. Neuropharmacology. 2010 Sep-Oct;59 (4-5) :353-7.